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Introduction
============

Depth of invasion (DOI) is defined as the length measured from the tumor surface to the deepest point of invasive tumor in a paraffin embedded section \[[@REF1]\]. The cut-off commonly used to stratify patients into low and high risk is 4 mm \[[@REF2]\]. DOI is an important prognostic factor for nodal metastasis in oral tongue cancer, with increasing DOI associated with nodal involvement and worse prognosis \[[@REF3]-[@REF7]\].

Recent studies demonstrated no benefit to adding radiation therapy (RT) for deeper tumors \[[@REF5]-[@REF9]\]. O\'steen et al. retrospectively evaluated the outcomes of 32 patients with stage N0-2b oral tongue or floor of mouth cancers with the primary tumor not crossing the midline who underwent PORT. The DOI in \>75% patients was \>4 mm, \>75% had positive or close (\<5 mm) margins and 38% had perineural invasion (PNI). RT to contralateral (CL) neck was omitted. At a median follow-up of 5.5 years among patients alive at the end of the study, there were no isolated nodal recurrences despite the majority of tumors possessing of DOI \>4 mm. The authors concluded that the risk of nodal recurrence when omitting CL neck RT was very low if the primary tumor did not cross the midline, irrespective of other risk factors \[[@REF5]\].

Rajappa et al. evaluated 375 pT1-2N0 oral tongue cancer patients. The cohort's median age was 49, and 93% had squamous cell carcinomas, with 37.6% and 5.87% possessing PNI and lympho-vascular invasion (LVI), respectively. PORT was delivered in 37.6% of the cohort for PNI/LVI in the majority of cases, and for close margins in the remaining patients. At a mean follow-up of 40.9 months, there was a 18.4% local recurrence rate, with a 12.7-month mean duration of recurrence. Forty-four percent of the recurrences were salvaged while the remainder developed distant metastasis (DM) or unresectable disease. The two- and five-year overall survival (OS) were 94.5% and 93.9%, respectively. The patients were further divided into three groups: DOI \<5 mm, 6-10 mm and \>10 mm, each of which were categorized into RT vs no-RT groups. Adding RT did not improve OS or disease-free survival (DFS) in any group \[[@REF8]\].

A National Cancer Database (NCDB) analysis of 934 patients with pathological T2N0 oral tongue cancers from 2004-2013 was performed to determine whether lesions with \>5 mm DOI benefitted from receiving PORT \[[@REF9]\]. Six hundred and seventy-seven (72.5%) patients had surgery alone and 257 (27.5%) received surgery plus PORT. Thirty-four (13.4%) received chemotherapy in addition to surgery and PORT. With a median follow-up of 28.4 months +/-10.4 months, the three-year OS was 81.3%. In multivariate analysis (MVA), adding PORT did not improve OS, even for patients with \>5 mm DOI (p = 0.769).

This study evaluates the potential benefit of PORT in pT1-2N0 (stage I and II) oral tongue cancers with a DOI \>4 mm.

Materials and methods
=====================

The NCDB is a national oncology database and the data represents \>70% newly diagnosed cancer cases and \>34 million historical records \[[@REF10]\]. This study was deemed to be exempt as per our Institutional review board. Patients with AJCC stage I and II oral tongue cancer diagnosed between 2006 and 2013 were queried. Inclusion criteria entailed oral cavity tumors (tongue) with wide excision, stage I and II, histology codes 8052, 8070-8078, and 8083. Patients receiving chemotherapy, had an OS less than six months, underwent any RT other than EBRT, or any residual tumor after surgical resection, were excluded from analysis.

Patients were stratified by receipt of PORT, elective neck dissection, and extent of tumor DOI (≤4 mm or \>4 mm). Kaplan-Meier analysis was performed to compare OS (using the log-rank test) between patients receiving and not receiving PORT. Multivariable Cox proportional hazards regression model was used to evaluate the independent effect of PORT on OS, while controlling for tumor DOI and other clinical characteristics. The patient inclusion flow diagram is shown in Figure [1](#FIG1){ref-type="fig"}.

![Patient inclusion flow diagram.](cureus-0011-00000006288-i01){#FIG1}

Results
=======

Patient characteristics are summarized in Table [1](#TAB1){ref-type="table"} and comparisons of patients in the \<4 mm DOI and \>4 mm DOI groups are shown in Tables [2](#TAB2){ref-type="table"}, [3](#TAB3){ref-type="table"}. Ninety-eight (10.5%) patients received RT while 841 (89.5%) did not. Overall, a greater percentage of patients did not receive PORT. This trend persevered among each tumor stage. Additionally, African Americans were less likely to undergo PORT. In addition, the patients not receiving PORT were more likely to have LVI in the \<4 mm category.

###### Patient characteristics by post-operative radiation therapy (PORT) status.

\*All continuous variables were analyzed using the Wilcoxon rank sum test, and all categorical variables were analyzed using the Chi-squared test, except those denoted with †, in which Fisher's exact test was used.

  ------------------------------------------------------------------------------------------------- ------ ------------------------ ----- ------------------------ -----------
                                                                                                    PORT                                  No PORT                   
  Characteristic                                                                                    N      Mean (SD) or Freq. (%)   N     Mean (SD) or Freq. (%)   p-value\*
  Age at Diagnosis                                                                                  98     57.8 (14.0)              841   59.5 (15.0)              0.346
  Sex                                                                                               98                              841                             
   Male                                                                                             57     58.2%                    443   52.7%                    0.303
   Female                                                                                           41     41.8%                    398   47.3%                     
  Race                                                                                              98                              841                             
   Black                                                                                            7      7.1%                     15    1.8%                     0.015^†^
   White                                                                                            84     85.7%                    780   92.8%                     
   Others                                                                                           6      6.1%                     36    4.3%                      
   Unknown                                                                                          1      1.0%                     10    1.2%                      
  Time from Diagnosis to Treatment (Days)                                                           98     26.2 (19.0)              803   28.5 (31.9)              0.865
  Time from Diagnosis to Surgery (Days)                                                             98     28.1 (19.3)              803   33.9 (32.1)              0.124
  Time from Diagnosis to Radiation Therapy (Days)                                                   98     79.0 (27.8)              0     \--                      \--
  Tumor Grade                                                                                       98                              841                             
  Well differentiated, differentiated, NOS                                                          23     23.5%                    275   32.7%                    0.124
  Moderately differentiated, moderately well differentiated, intermediate differentiation           56     57.1%                    435   51.7%                     
  Poorly differentiated                                                                             15     15.3%                    83    9.9%                      
  Cell type not determined, not stated or not applicable, unknown primaries, high-grade dysplasia   4      4.1%                     48    5.7%                      
  Clinical Stage                                                                                    98                              841                             
  Stage I                                                                                           39     39.8%                    612   72.8%                    \<0.001
  Stage II                                                                                          59     60.2%                    229   27.2%                     
  Pathological Stage                                                                                98                              841                             
  Stage I                                                                                           50     51.0%                    670   79.7%                    \<0.001
  Stage II                                                                                          48     49.0%                    171   20.3%                     
  Analytic Stage                                                                                    98                              841                             
  Stage I                                                                                           50     51.0%                    670   79.7%                    \<0.001
  Stage II                                                                                          48     49.0%                    171   20.3%                     
  Tumor Depth                                                                                       98                              841                             
  ≤4 mm                                                                                             62     63.3%                    657   78.1%                    0.001
  \>4 mm                                                                                            36     36.7%                    184   21.9%                     
  Regional Lymph Node Surgery                                                                       98                              841                             
  Yes                                                                                               80     81.6%                    553   65.8%                    0.002
  No                                                                                                18     18.4%                    288   34.2%                     
  Lymph Vascular Invasion                                                                           93                              813                             
  Present                                                                                           12     12.9%                    31    3.8%                     0.006^†^
  Not present                                                                                       70     75.3%                    681   83.8%                     
  Not applicable                                                                                    1      1.1%                     9     1.1%                      
  Unknown                                                                                           10     10.8%                    92    11.3%                     
  ------------------------------------------------------------------------------------------------- ------ ------------------------ ----- ------------------------ -----------

###### Characteristics of patients with tumor depth ≤4 mm by post-operative radiation therapy (PORT) status.

\*All continuous variables were analyzed using the Wilcoxon rank sum test, and all categorical variables were analyzed using the Chi-squared test, except those denoted with †, in which Fisher's exact test was used.

  ------------------------------------------------------------------------------------------------- ------ ------------------------ ----- ------------------------ -----------
                                                                                                    PORT                                  No PORT                   
  Characteristic                                                                                    N      Mean (SD) or Freq. (%)   N     Mean (SD) or Freq. (%)   p-value\*
  Age at Diagnosis                                                                                  62     56.9 (14.0)              657   59.6 (15.1)              0.158
  Sex                                                                                               62                              657                             
   Male                                                                                             35     56.5%                    343   52.2%                    0.522
   Female                                                                                           27     43.6%                    314   47.8%                     
  Race                                                                                              62                              657                             
   Black                                                                                            3      4.8%                     11    1.7%                     0.273^†^
   White                                                                                            56     90.3%                    609   92.7%                     
  Others                                                                                            2      3.2%                     29    4.4%                      
  Unknown                                                                                           1      1.6%                     8     1.2%                      
  Time from Diagnosis to Treatment (Days)                                                           62     28.0 (19.9)              657   28.9 (34.4)              0.435
  Time from Diagnosis to Surgery (Days)                                                             62     29.3 (18.8)              657   34.9 (34.6)              0.360
  Time from Diagnosis to Radiation Therapy (Days)                                                   62     78.4 (28.2)              0       \--                      \--
  Tumor Grade                                                                                       62                              657                             
  Well differentiated, differentiated, NOS                                                          16     25.8%                    233   35.5%                    0.078
  Moderately differentiated, moderately well differentiated, intermediate differentiation           33     53.2%                    320   48.7%                     
  Poorly differentiated                                                                             11     17.7%                    61    9.3%                      
  Cell type not determined, not stated or not applicable, unknown primaries, high-grade dysplasia   2      3.2%                     43    6.5%                      
  Clinical Stage                                                                                    62                              657                             
    Stage I                                                                                         25     40.3%                    502   76.4%                    \<0.001
    Stage II                                                                                        37     59.7%                    155   23.6%                     
  Pathological Stage                                                                                62                              657                             
    Stage I                                                                                         33     53.2%                    538   81.9%                    \<0.001
    Stage II                                                                                        29     46.8%                    119   18.1%                     
  Analytic Stage                                                                                    62                              657                               
    Stage I                                                                                         33     53.2%                    538   81.9%                    \<0.001
    Stage II                                                                                        29     46.8%                    119   18.1%                     
  Regional Lymph Node Surgery                                                                       62                              657                             
   Yes                                                                                              52     83.9%                    402   61.2%                    \<0.001
   No                                                                                               10     16.1%                    255   38.8%                     
  Lymph Vascular Invasion                                                                           58                              631                             
  Present                                                                                           8      13.8%                    19    3.0%                     0.005^†^
  Not present                                                                                       44     75.9%                    528   83.7%                     
  Not applicable                                                                                    1      1.7%                     9     1.4%                      
  Unknown                                                                                           5      8.6%                     75    11.9%                     
  ------------------------------------------------------------------------------------------------- ------ ------------------------ ----- ------------------------ -----------

###### Characteristics of patients with tumor depth \>4 mm by post-operative radiation therapy (PORT) status.

\*All continuous variables were analyzed using the Wilcoxon rank sum test, and all categorical variables were analyzed using the Chi-squared test, except those denoted with †, in which Fisher's exact test was used.

  ------------------------------------------------------------------------------------------------- ------ ------------------------ ----- ------------------------ -----------
                                                                                                    PORT                                  No PORT                   
  Characteristic                                                                                    N      Mean (SD) or Freq. (%)   N     Mean (SD) or Freq. (%)   p-value\*
  Age at Diagnosis                                                                                  36     59.3 (14.1)              184   59.1 (14.8)              0.704
  Sex                                                                                               36                              184                             
   Male                                                                                             22     61.1%                    100   54.4%                    0.455
   Female                                                                                           14     38.9%                    84    45.7%                     
  Race                                                                                              36                              184                             
   Black                                                                                            4      11.1%                    4     2.2%                     0.014^†^
   White                                                                                            28     77.8%                    171   92.9%                     
   Others                                                                                           4      11.1%                    7     3.8%                      
   Unknown                                                                                          0      0%                       2     1.1%                      
  Time from Diagnosis to Treatment (Days)                                                           36     23.2 (17.3)              175   26.9 (20.5)              0.397
  Time from Diagnosis to Surgery (Days)                                                             36     26.0 (20.2)              175   30.0 (20.9)              0.284
  Time from Diagnosis to Radiation Therapy (Days)                                                   36     79.9 (27.5)              0     \--                      \--
  Tumor Grade                                                                                       36                              184                             
  Well differentiated, differentiated, NOS                                                          7      19.4%                    42    22.8%                    0.763^†^
  Moderately differentiated, moderately well differentiated, intermediate differentiation           23     63.9%                    115   62.5%                     
  Poorly differentiated                                                                             4      11.1%                    22    12.0%                     
  Cell type not determined, not stated or not applicable, unknown primaries, high-grade dysplasia   2      5.6%                     5     2.7%                      
  Clinical Stage                                                                                    36                              184                             
    Stage I                                                                                         14     38.9%                    110   59.8%                    0.021
    Stage II                                                                                        22     61.1%                    74    40.2%                     
  Pathological Stage                                                                                36                              184                             
   Stage I                                                                                          17     47.2%                    132   71.7%                    0.004
  Stage II                                                                                          19     52.8%                    52    28.3%                     
  Analytic Stage                                                                                    36                              184                             
   Stage I                                                                                          17     47.2%                    132   71.7%                    0.004
   Stage II                                                                                         19     52.8%                    52    28.3%                     
  Regional Lymph Node Surgery                                                                       36                              184                             
  Yes                                                                                               28     77.8%                    151   82.1%                    0.546
  No                                                                                                8      22.2%                    33    17.9%                     
  Lymph Vascular Invasion                                                                           35                              182                             
  Present                                                                                           4      11.4%                    12    6.6%                     \--
  Not present                                                                                       26     74.3%                    153   84.1%                     
  Not applicable                                                                                    0      0%                       0     0%                        
  Unknown                                                                                           5      14.3%                    17    9.3%                      
  ------------------------------------------------------------------------------------------------- ------ ------------------------ ----- ------------------------ -----------

For tumors \<4 mm DOI, adding RT did not improve survival (p = 0.634). OS was similar in patients with DOI \>4 mm with or without RT (p = 0.816) (Figure [2](#FIG2){ref-type="fig"}). Among those with tumor DOI \<4 mm, clinical stage I patients trended towards improved OS compared to patients with clinical stage II tumors (p = 0.07), and those with pathological stage I tumors trended towards improved OS in comparison to pathological stage II lesions (p = 0.087). There was no difference in OS with respect to clinical stage (p = 0.445) (Figure [3](#FIG3){ref-type="fig"}), and pathological stage (p = 0.108) (Figure [4](#FIG4){ref-type="fig"}) among patients with a tumor DOI \>4 mm.

![Overall survival by PORT status with DOI: (A) \<4 mm, (B) \>4 mm.\
PORT: Post-operative radiotherapy; DOI: Depth of invasion.](cureus-0011-00000006288-i02){#FIG2}

![Overall survival by clinical stage with DOI: (A) \<4 mm, (B) \>4 mm.\
DOI: Depth of invasion](cureus-0011-00000006288-i03){#FIG3}

![Overall survival by pathological stage with DOI: (A) \<4 mm, (B) \>4 mm.\
DOI: Depth of invasion](cureus-0011-00000006288-i04){#FIG4}

While elective neck dissection (END) did not impact OS for lesions with DOI \<4 mm (p = 0.128), it did confer a survival benefit for lesions with DOI \>4 mm (p = 0.01) (Figure [5](#FIG5){ref-type="fig"}).

![Overall survival by elective neck surgery for tumors with DOI: (A) \<4 mm, (B) \>4 mm.\
DOI: Depth of invasion](cureus-0011-00000006288-i05){#FIG5}

On multivariable survival analysis, END remained associated with an improved OS in the subset of patients with a DOI \>4 mm (hazard ratio of death, 0.37; 95% confidence interval, 0.17-0.81 \[p = 0.012\]), when also controlling for age, sex, PORT status, clinical stage, and pathological stage (Tables [4](#TAB4){ref-type="table"}, [5](#TAB5){ref-type="table"}).

###### Multivariable Cox regression model for overall survival (OS) tumor depth ≤4 mm.

PORT: Post-operative radiotherapy

  ----------------------------- ----------------------- ---------
  Characteristic                Hazard Ratio (95% CI)   p-Value
  PORT                                                   
  No                            \--                     \--
  Yes                           1.11 (0.54, 2.27)       0.782
  Age                           1.03 (1.01, 1.05)       \<0.001
  Sex                                                    
  Male                          \--                     \--
  Female                        0.84 (0.54, 1.30)       0.425
  Clinical Stage                                         
  Stage I                       \--                     \--
  Stage II                      1.55 (0.83, 2.90)       0.172
  Pathological Stage                                     
  Stage I                       \--                     \--
  Stage II                      1.27 (0.66, 2.45)       0.482
  Regional Lymph Node Surgery                            
  No                            \--                     \--
  Yes                           0.72 (0.45, 1.14)       0.159
  ----------------------------- ----------------------- ---------

###### Multivariable Cox regression model for overall survival (OS) tumor depth \>4 mm.

PORT: Post-operative radiotherapy

  ----------------------------- ----------------------- ---------
  Characteristic                Hazard Ratio (95% CI)   p-Value
  PORT                                                   
  No                            \--                     \--
  Yes                           0.80 (0.32, 2.01)       0.641
  Age                           1.04 (1.01, 1.07)       0.011
  Sex                                                    
  Male                          \--                     \--
  Female                        0.69 (0.33, 1.44)       0.319
  Clinical Stage                                         
  Stage I                       \--                     \--
  Stage II                      1.03 (0.42, 2.57)       0.943
  Pathological Stage                                     
  Stage I                       \--                     \--
  Stage II                      2.00 (0.82, 4.89)       0.129
  Regional Lymph Node Surgery                            
  No                            \--                     \--
  Yes                           0.37 (0.17, 0.81)        
  ----------------------------- ----------------------- ---------

Discussion
==========

This population-based study of stage I and II oral tongue cancers showed a survival benefit of elective neck dissection in patients with DOI \>4 mm, but no benefit of adding adjuvant RT in regard of less of DOI.

Numerous studies identify DOI as a poor prognostic factor. A retrospective Japanese study of 337 stage I-II tongue cancer patients undergoing surgical resection revealed that T stage, DOI (cut-off was 4 mm), tumor budding (the presence of a single cancer cell or cluster of less than five cancer cells at the invasive front) and adjacent tissue at the invasive front are predictive of delayed neck metastasis \[[@REF11]\].

Although 4 mm is commonly considered the DOI cut off for significance, a retrospective study of DOI cut-off points in previously untreated early stage oral tongue cancers showed 7.25 mm to be most predictive of occult nodal metastasis, 8 mm for OS and DFS \[[@REF3]\]. In another retrospective study of 93 early stage oral lung cancer patients undergoing primary resection without neck dissection, 47.4% had nodal recurrence, with 19.7% recurred at the primary site. Cox-proportional polynomial analysis showed an increasing hazard of recurrence with DOI between 2-6 mm \[[@REF4]\].

Ganly et al. sought to determine factors associated with tumor recurrence in a cohort of 216 patients with oral tongue cancers. Half of the lesions were T2, 83% underwent surgery and 17% underwent surgery and PORT. At a median follow-up of 80 months, MVA revealed DOI as an independent predictor of neck relapse-free survival, with a DOI \>2 mm conferring 3.7-fold higher risk of recurrence compared to DOI \<2 mm \[[@REF12]\].

A retrospective review evaluated outcomes of 103 patients with T1 or T2 N0 oral tongue cancers who underwent surgical resection with negative margins and DOI \>4 mm. Sixty-two patients received PORT and 41 did not. With a median follow-up of 41.3 months, there was no difference between PORT versus no PORT \[[@REF13]\].

Shim et al. reviewed the medical records of 86 patients with oral tongue cancers, of which 58% were stage I, 26% stage II and 16% stage III. Among the 16% receiving PORT, they reported no difference in recurrence rates for tumors \>0.5 cm compared to those who did not receive PORT \[[@REF14]\]. Table [6](#TAB6){ref-type="table"} summarizes select studies evaluating DOI as a prognostic factor.

###### Select studies evaluating DOI as a prognostic factor.

DOI: Depth of invasion; MVA: Multivariate analysis; LVI: Lympho-vascular invasion; PNI: Perineural invasion; HPV: Human papillomavirus.

  ------------------------------------- ------------------------------------------------------------------------------ ----------------- ------------------------------------------------------------------------------------------------ -----------------------------------------------------------------------
  Author, year (reference)              Study design                                                                   Significant DOI   Outcomes                                                                                         Comments
  Fukano et al., 1997 \[[@REF15]\]      Retrospective, 34 patients, oral tongue cancer                                 5 mm              \>5 mm, neck metastasis 64.7%                                                                    For DOI \> 5 mm, suggestion is to operate or radiate neck
  Asakage et al., 1998 \[[@REF16]\]     Retrospective, 44 patients, oral tongue, stage I/II partial glossectomy only   4 mm              Cervical metastasis in 21/44 patients, \>4 mm only factor significant in MVA                     Recommended supraomohyoid neck dissection in tumors \> 4 mm.
  Kurokawa et al., 2002 \[[@REF17]\]    Retrospective, 50 patients, stage I/II oral tongue, only partial glossectomy   4 mm              Overall cervical metastasis rate of 14%, MVA showed DOI \> 4 mm as the significant risk factor   Recommended to electively treat the neck for DOI \> 4 mm
  Goodman et al., 2009 \[[@REF18]\]     SEER, DOI, LVI and PNI assessed with respect to mortality                      3 mm              MVI showed DOI and PNI were significant predictors of OS                                          
  Ling et al., 2013 \[[@REF19]\]        Retrospective, 210 patients with tongue cancer                                 9 mm              DOI \> 9 mm 7.7 times more likely to die than tumors \<4 mm                                      To improve survival in such patients, surgical resection recommended.
  Almangush et al., 2014 \[[@REF20]\]   Retrospective study of 233 patients with stage I/II oral tongue cancers        4 mm              Tumor budding and DOI \> 4 mm associated with worse prognosis                                    Recommended multimodality therapy for deep tumors.
  Masood et al., 2018 \[[@REF21]\]      Retrospective study, 67 patients with T1/2N0 oral tongue cancer HPV-           5 mm              DOI \> 5 mm associated with risk of LVI and nodal metastasis                                     No specific recommendation made regarding management.
  ------------------------------------- ------------------------------------------------------------------------------ ----------------- ------------------------------------------------------------------------------------------------ -----------------------------------------------------------------------

Limitations of our study include its retrospective nature, relatively small number in the total group receiving RT and lack of data on details of treatment such as technique of RT, use of image guidance and dose, local control and toxicity. Select studies evaluating DOI as a prognostic factor are listed in Table [6](#TAB6){ref-type="table"}. In clinical practice, DOI does dictate neck dissection based on risk of neck metastasis although we show survival benefit with END in DOI \> 4 mm. RT is associated with significant side effects including mucositis, pain, dysphagia, necrosis, dry mouth and loss of taste, and can be avoided for early stage tongue cancers.

Conclusions
===========

Our study is the first large population-based study of both stage I and II oral cavity cancers to show addition of elective neck irradiation for tumors \>4 mm does not improve survival. However, elective neck dissection in oral tongue cancers with DOI \>4 mm confers a positive survival benefit.
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